Sun Pharma announces closure of merger deal with Ranbaxy
Sun Pharmaceutical Industries Ltd. begins the integration of Ranbaxy’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth. The merger has fortified Sun Pharma’s position as the world’s fifth largest specialty generic pharmaceutical company and the top ranking Indian Pharma company with significant lead in market share. The combined entity’s manufacturing footprint covers 5 continents with products sold in over 150 nations with a stronger presence in US, India, Asia, Europe, South Africa, CIS & Russia and Latin America. Sun Pharma now offers a large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs as well as a ready foray into the global consumer healthcare market.
Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both companies will work together to leverage this relationship for global business growth. The integrated culture theme, “Growing Together”, represents the core objective of this merger focusing on improving productivity, compliance commitment, focus on quality and sustainable growth. Through this merger Sun Pharma emerges as India’s first truly global pharmaceutical company.
Following the closure of this transaction, Ranbaxy will be delisted from the Indian Stock Exchanges. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. On pro forma basis for 12 months ended December 2014, Sun Pharma’s gross margin stands at 76% (Industry average 62%); EBIDTA margin at 32% (industry average 19%) and Net margin at 20% (Industry average 12%).
Mr Israel Makov, Chairman, Sun Pharma said, “The combined entity will capitalize on the expanded global footprint and enhance our dominance as a world leader in the specialty generics landscape. Sun remains committed to uncompromised product quality, 100% compliance and promotes innovation to create the most dynamic global specialty generics pharmaceutical company. We believe that our shareholders, customers and employees will share our excitement in the potential of this combination and thank them for their continued support.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Can gut infection trigger Parkinson's disease?
Breakthrough for peptide medication - The “Holy Grail” of peptide chemistry: Making peptide active agents available orally
Impending Patent Expiries of Blockbuster Biologics Creates Huge Market Opportunity for European Biosimilars Manufacturers, States Frost & Sullivan - Seamlessly Integrated R&D, Production, Sales and Marketing Processes to Ensure Success in this High Growth Market
Study gives clues to how adrenal cancer forms - Dysfunctional telomeres can trigger cancer mutations, U-M researchers find
BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer - Medigene will receive EUR 26 million upfront from BioNTech
Bioconjugation specialist Innova Biosciences acquired by SYGNIS AG - Innova CEO and CSO Dr. Nick Gee becomes Chief Technical Officer of SYGNIS
Antibiotics resistance: Carbapenemase-producing germs in livestock populations
'Trojan horse' anticancer drug disguises itself as fat - Promising system delivers chemo drug straight into tumors with fewer side effects
Daiichi Sankyo to Acquire Ambit Biosciences
Bug splatter on your car’s windshield is a treasure trove of genomic biodiversity
